Literature DB >> 31999544

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.

Alan I So1, Kim N Chi2, Brita Danielson3, Neil E Fleshner4, Anil Kapoor5, Tamim Niazi6, Frederic Pouliot7, Ricardo A Rendon8, Bobby Shayegan5, Srikala Sridhar9, Eric Vigneault10, Fred Saad11.   

Abstract

Entities:  

Year:  2019        PMID： 31999544      PMCID： PMC7012288          DOI： 10.5489/cuaj.6384

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  41 in total

Review 1.  Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.

Authors:  F Kunath; P J Goebell; B Wullich; D Sikic; A Kahlmeyer
Journal:  World J Urol       Date:  2019-03-04       Impact factor: 4.226

2.  The placenta harbors a unique microbiome.

Authors:  Kjersti Aagaard; Jun Ma; Kathleen M Antony; Radhika Ganu; Joseph Petrosino; James Versalovic
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

3.  Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.

Authors:  Tracy R Glass; Catherine M Tangen; E David Crawford; Ian Thompson
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

4.  Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.

Authors:  S Eriksson; A Eriksson; R Stege; K Carlström
Journal:  Calcif Tissue Int       Date:  1995-08       Impact factor: 4.333

5.  Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

Authors:  Gwenaelle Gravis; Jean-Marie Boher; Karim Fizazi; Florence Joly; Franck Priou; Patricia Marino; Igor Latorzeff; Remy Delva; Ivan Krakowski; Brigitte Laguerre; Jochen Walz; Fréderic Rolland; Christine Théodore; Gael Deplanque; Jean-Marc Ferrero; Damien Pouessel; Loïc Mourey; Philippe Beuzeboc; Sylvie Zanetta; Muriel Habibian; Jean-François Berdah; Jerome Dauba; Marjorie Baciuchka; Christian Platini; Claude Linassier; Jean-Luc Labourey; Jean Pascal Machiels; Claude El Kouri; Alain Ravaud; Etienne Suc; Jean-Christophe Eymard; Ali Hasbini; Guilhem Bousquet; Michel Soulie; Stéphane Oudard
Journal:  Eur Urol       Date:  2014-09-30       Impact factor: 20.096

6.  Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Giri Sulur; Yesenia Luna; Susan Li; Suneel Mundle; Kim N Chi
Journal:  Lancet Oncol       Date:  2019-04-12       Impact factor: 41.316

7.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

8.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Authors:  Matthew R Smith; James Eastham; Donald M Gleason; Daniel Shasha; Simon Tchekmedyian; Norman Zinner
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

9.  Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women.

Authors:  Hua Bai; Danqing Jing; Aitao Guo; Shinan Yin
Journal:  J Int Med Res       Date:  2013-05-13       Impact factor: 1.671

10.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321
View more
  7 in total

1.  Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.

Authors:  Bobby Shayegan; Christopher J D Wallis; Robert J Hamilton; Scott C Morgan; Ilinas Cagiannos; Naveen S Basappa; Cristiano Ferrario; Geoffrey T Gotto; Ricardo Fernandes; Soumyajit Roy; Krista L Noonan; Tamim Niazi; Sebastien J Hotte; Fred Saad; Huong Hew; Laura Park-Wyllie; Katherine F Y Chan; Shawn Malone
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-02-23       Impact factor: 5.554

2.  Canadian Urological Association best practice report: Bone health in prostate cancer.

Authors:  Luke T Lavallée; Ryan McLarty; Christopher Tran; Rodney H Breau; Patrick Richard; Bobby Shayegan; Brita Danielson; Marie-Paul Jammal; Fred Saad
Journal:  Can Urol Assoc J       Date:  2021-12       Impact factor: 1.862

Review 3.  The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.

Authors:  Ivan Yanev; Jessy Gatete; Armen G Aprikian; Jason Robert Guertin; Alice Dragomir
Journal:  Curr Oncol       Date:  2022-05-07       Impact factor: 3.109

4.  Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer.

Authors:  Madonna R Peter; Misha Bilenky; Alastair Davies; Ruth Isserlin; Gary D Bader; Neil E Fleshner; Martin Hirst; Amina Zoubeidi; Bharati Bapat
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

5.  Evaluation of the reporting quality of clinical practice guidelines on prostate cancer using the RIGHT checklist.

Authors:  Kefeng Liu; Yanfang Ma; Yongjie Yang; Jingli Lu; Jie Zhao; Shuzhang Du; Xuepei Zhang; Chunlei Liu; Francesco Del Giudice; Masaki Shiota; Shingo Hatakeyama; Xiaojian Zhang; Jian Kang
Journal:  Ann Transl Med       Date:  2021-07

6.  Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer.

Authors:  Christopher J D Wallis; Shawn Malone; Ilias Cagiannos; Scott C Morgan; Robert J Hamilton; Naveen S Basappa; Cristiano Ferrario; Geoffrey T Gotto; Ricardo Fernandes; Tamim Niazi; Krista L Noonan; Fred Saad; Sebastien J Hotte; Huong Hew; Katherine F Y Chan; Laura Park Wyllie; Bobby Shayegan
Journal:  JNCI Cancer Spectr       Date:  2021-10-01

Review 7.  Recommendations on Weight Loss and Healthy Lifestyle in Prostate Cancer Clinical Guidelines: A Systematic Review.

Authors:  Mario Rivera-Izquierdo; Virginia Martínez-Ruiz; José Juan Jiménez-Moleón
Journal:  Int J Environ Res Public Health       Date:  2022-01-27       Impact factor: 3.390
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.